F-18 FLT PET: A Noninvasive Diagnostic Tool for Visualization of the Bone Marrow Compartment in Patients With Aplastic Anemia

Agool, Ali; Slart, Riemer H. J. A.; Kluin, Philip M.; Wolf, Jtm de; Dierckx, Rudi; Vellenga, Edo

doi:10.1097/rlu.0b013e31820aa1a1

Cited by 26 publications

(21 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, 18 F-FLT PET also has been used to measure the health and proliferation of the marrow, especially in patients undergoing bone marrow transplantation (12). 18 F-FLT PET imaging was found useful in evaluating bone marrow in patients with aplastic anemia (13). Interestingly, the main characteristic of 18 F-FLT PET in patients with extramedullary hematopoiesis was higher uptake in the spleen and liver (14).…”

Section: Bone Marrow and Hematologic Malignanciesmentioning

confidence: 99%

PET Imaging of Proliferation with Pyrimidines

Tehrani

Shields

2013

J Nucl Med

View full text Add to dashboard Cite

show abstract

Section: Bone Marrow and Hematologic Malignanciesmentioning

confidence: 99%

PET Imaging of Proliferation with Pyrimidines

Tehrani

Shields

2013

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…Agool et al studied a group of 18 patients with different hematologic disorders, among which were two patients with MM. The authors found that the affected osteolytic areas in these two MM patients demonstrated a low 18 F-FLT uptake [56]. In a pilot study on combined 18 F-FDG and 18 F-FLT PET/CT imaging in 8 myeloma patients (4 patients with symptomatic MM, 4 patients with SMM) the number of myeloma-indicative lesions was significantly higher for 18 F-FDG PET/CT than for 18 F-FLT PET/CT.…”

Section: F-fluorothymidine ( 18 F-flt)mentioning

confidence: 93%

Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma

Sachpekidis

Goldschmidt

Dimitrakopoulou-Strauß

2019

Molecules

View full text Add to dashboard Cite

Multiple myeloma (MM) is a plasma cell disorder, characterized by clonal proliferation of malignant plasma cells in the bone marrow. Bone disease is the most frequent feature and an end-organ defining indicator of MM. In this context, imaging plays a pivotal role in the management of the malignancy. For several decades whole-body X-ray survey (WBXR) has been applied for the diagnosis and staging of bone disease in MM. However, the serious drawbacks of WBXR have led to its gradual replacement from novel imaging modalities, such as computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT). PET/CT, with the tracer 18 F-fluorodeoxyglucose ( 18 F-FDG), is now considered a powerful diagnostic tool for the detection of medullary and extramedullary disease at the time of diagnosis, a reliable predictor of survival as well as the most robust modality for treatment response evaluation in MM. On the other hand, 18 F-FDG carries its own limitations as a radiopharmaceutical, including a rather poor sensitivity for the detection of diffuse bone marrow infiltration, a relatively low specificity, and the lack of widely applied, established criteria for image interpretation. This has led to the development of several alternative PET tracers, some of which with promising results regarding MM detection. The aim of this review article is to outline the major applications of PET/CT with different radiopharmaceuticals in the clinical practice of MM.

show abstract

“…It has clear contrast advantages over 18F-FDG in the brain and urinary tract owing to the relatively low overall cellular turnover in these organs, but the high normal cellular proliferation in the bone marrow limits its value here (Shields, 2003 ). Its high bone marrow uptake has, in fact, led to its being used to visualize the total distribution of the hematopoietic bone marrow compartment in aplastic anaemia (Agool et al , 2011 ). The same problem in differentiating malignancy from rapidly proliferating normal tissue applies to lymph nodes, where benign reactive hyperplasia is associated with a high proliferative rate, and 18F-FLT has shown poor specifi city (17%) in the detection of nodal metastases (Troost et al , 2007 ).…”

Section: -F Fl Uoro-l-thymidine (Flt)mentioning

confidence: 98%